Filing summary
Entity and period: This is Point Capital, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013, not a filing identified in its text as Silo Pharma, Inc. The company was a development-stage issuer. It merged with inactive Point Capital, Inc. on January 24, 2013, changing its name from Gold Swap, Inc. and its state of incorporation from New York to Delaware.
Financial results and position
| Metric | Q1 2013 / March 31, 2013 | Comparable period / December 31, 2012 |
|---|---|---|
| Revenue | None; no revenue since inception | None reported since inception |
| General and administrative expense | $22,882 | $13,039 in Q1 2012 |
| Net loss | $22,882 | $13,039 in Q1 2012 |
| Cash and cash equivalents | $10,096 | $279 |
| Net cash used in operating activities | $10,183 | $13,039 in Q1 2012 |
| Total liabilities | $54,172 | $41,473 |
| Stockholders’ deficit | $44,076 | $41,194 |
There was no operating revenue or reported operating margin. Q1 2013 expenses and loss increased by $9,843 year over year, which management attributed primarily to professional fees related to the merger and name change. Q1 financing provided $20,000 from an issuance of 100,000 common shares; cash increased by $9,817.
At March 31, current assets were $10,096 and current liabilities were $54,172, a working capital deficit of $44,076. The balance sheet lists $20,000 of current notes payable and $1,065 of current interest payable. It shows no long-term liabilities at March 31, although prior-year figures and the note-payable disclosures warrant checking the debt classification.
Outlook, risks, and notable items
- Management estimated next-12-month working-capital needs of $95,000 and a monthly burn rate of $8,000, and said available cash would meet requirements for at least 12 months. The filing also reports $400,000 of cash as of May 13, 2013, following a subsequent April 24 sale of 4,000 Series A convertible preferred shares for $400,000.
- The preferred shares convert at $0.20 per common share, have a $100-per-share liquidation value, and have no stated dividend rate. The filing describes redemption rights upon specified triggering events and conditional company-forced conversion rights.
- The company had not established a definitive business direction: it described plans for a precious-metals and jewelry recycling business while also considering becoming a business development company and providing financing to smaller businesses. It had no employees other than officers and no commitments for capital expenditures.
- The company warned of development-stage business risks, including financing and potential business failure, and stated that additional capital may not be available if needed. Management’s cash runway estimate is forward-looking, not a guarantee.
- The filing reports no pending legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor verification priorities
- Confirm the issuer identity: the supplied request names Silo Pharma, Inc., but this filing names Point Capital, Inc.
- Verify the April 2013 preferred-stock issuance, the reported May cash balance, and the preferred shares’ conversion, redemption, and potential dilution terms.
- Reconcile the balance-sheet presentation of notes payable and accrued interest with the debt terms in the notes, including maturity and current versus long-term classification.
- Assess whether the stated $95,000 working-capital requirement, $8,000 monthly burn estimate, and claimed 12-month runway remain supportable given the company’s business uncertainty and lack of revenue.